









市場行情
/
股票
/
nasdaq-crbu
/

Caribou Biosciences Inc

CRBU

1.720USD

+0.040+2.38%

收盤 12/22, 16:00（美東）報價延遲15分鐘

160.77M總市值

虧損本益比TTM



Caribou Biosciences Inc

1.720

+0.040+2.38%

概覽公司財務分析

概覽

公司

財務

分析

關於 Caribou Biosciences Inc 公司

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Caribou Biosciences Inc簡介



公司代碼CRBU

公司名稱Caribou Biosciences Inc

上市日期Jul 23, 2021

CEOHaurwitz (Rachel E)

員工數量147

證券類型Ordinary Share

年結日Jul 23

公司地址2929 7Th Street, Ste 120

城市BERKELEY

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94710

電話15109826030

網址https://www.cariboubio.com/

公司代碼CRBU

上市日期Jul 23, 2021

CEOHaurwitz (Rachel E)

Caribou Biosciences Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Barbara G. McClung, J.D.

Chief Legal Officer, Corporate Secretary

381.25K

-7.13%

Mr. Sriram (Sri) Ryali

Chief Financial Officer

17.36K

Ms. Ruhi A. Khan

Chief Business Officer

Dr. Nancy C. Whiting, Pharm.D.

Independent Director

Mr. David Louis Johnson

Independent Director

Dr. Dara Richardson-Heron, M.D.

Independent Director

Dr. Tina Albertson, M.D., Ph.D.

Chief Medical Officer

Dr. Natalie R. Sacks, M.D.

Independent Director

Mr. Andrew L. Guggenhime

Independent Chairman of the Board

Dr. Scott N. Braunstein, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Ms. Barbara G. McClung, J.D.

Chief Legal Officer, Corporate Secretary

381.25K

-7.13%

Mr. Sriram (Sri) Ryali

Chief Financial Officer

17.36K

Ms. Ruhi A. Khan

Chief Business Officer

Dr. Nancy C. Whiting, Pharm.D.

Independent Director

Mr. David Louis Johnson

Independent Director

Dr. Dara Richardson-Heron, M.D.

Independent Director

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

1.66M

62.32%

Rest of world

1.00M

37.68%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Pfizer Inc

5.02%

The Vanguard Group, Inc.

4.52%

Haurwitz (Rachel E. Ph.D.)

3.68%

Millennium Management LLC

3.44%

Kynam Capital Management LP

3.28%

其他

80.06%

持股股東

佔比

Pfizer Inc

5.02%

The Vanguard Group, Inc.

4.52%

Haurwitz (Rachel E. Ph.D.)

3.68%

Millennium Management LLC

3.44%

Kynam Capital Management LP

3.28%

其他

80.06%

股東類型

持股股東

佔比

Investment Advisor

16.28%

Hedge Fund

13.43%

Investment Advisor/Hedge Fund

5.55%

Corporation

5.02%

Individual Investor

4.72%

Research Firm

2.40%

Private Equity

0.83%

Venture Capital

0.47%

Bank and Trust

0.05%

其他

51.25%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

336

36.52M

71.18%

+8.50K

2025Q3

343

36.51M

75.34%

-3.42M

2025Q2

344

39.93M

84.21%

-9.67M

2025Q1

343

49.60M

89.75%

-33.86M

2024Q4

341

57.02M

91.20%

-746.04K

2024Q3

336

56.25M

89.23%

-1.72M

2024Q2

332

57.28M

88.69%

-12.92M

2024Q1

319

69.74M

90.55%

-12.04M

2023Q4

311

71.96M

89.62%

-1.70M

2023Q3

307

73.59M

61.71%

+24.32M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Pfizer Inc

4.69M

5.04%

Jun 30, 2025

The Vanguard Group, Inc.

4.09M

4.39%

-432.17K

-9.56%

Jun 30, 2025

Haurwitz (Rachel E. Ph.D.)

3.44M

3.69%

-87.08K

-2.47%

Apr 22, 2025

Millennium Management LLC

1.55M

1.67%

+729.54K

+88.85%

Jun 30, 2025

Kynam Capital Management LP

3.07M

3.29%

-201.37K

-6.16%

Jun 30, 2025

Two Sigma Investments, LP

2.38M

2.55%

-112.17K

-4.51%

Jun 30, 2025

ACATIS Investment Kapitalverwaltungsgesellschaft GmbH

2.00M

2.15%

Jun 30, 2025

SELECTRA Management Company S.A.

1.50M

1.61%

-14.10K

-0.93%

Jul 31, 2025

BlackRock Institutional Trust Company, N.A.

1.83M

1.97%

-3.91M

-68.09%

Jun 30, 2025

abrdn Inc.

897.58K

0.96%

+486.44K

+118.31%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

AXS Green Alpha ETF

1.24%

WisdomTree BioRevolution Fund

0.52%

Avantis US Small Cap Equity ETF

0.01%

Schwab U.S. Small-Cap ETF

0.01%

DFA Dimensional US Core Equity Market ETF

Global X Genomics & Biotechnology ETF

ProShares Ultra Nasdaq Biotechnology

ProShares Hedge Replication ETF

Pacer WealthShield ETF

ProShares UltraPro Russell2000

AXS Green Alpha ETF

佔比1.24%

WisdomTree BioRevolution Fund

佔比0.52%

Avantis US Small Cap Equity ETF

佔比0.01%

Schwab U.S. Small-Cap ETF

佔比0.01%

DFA Dimensional US Core Equity Market ETF

佔比0%

Global X Genomics & Biotechnology ETF

佔比0%

ProShares Ultra Nasdaq Biotechnology

佔比0%

ProShares Hedge Replication ETF

佔比0%

Pacer WealthShield ETF

佔比0%

ProShares UltraPro Russell2000

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Caribou Biosciences Inc的前五大股東是誰？



Caribou Biosciences Inc的前五大股東如下：
Pfizer Inc
持有股份：4.69M
佔總股份比例：5.04%。
The Vanguard Group, Inc.
持有股份：4.09M
佔總股份比例：4.39%。
Haurwitz (Rachel E. Ph.D.)
持有股份：3.44M
佔總股份比例：3.69%。
Millennium Management LLC
持有股份：1.55M
佔總股份比例：1.67%。
Kynam Capital Management LP
持有股份：3.07M
佔總股份比例：3.29%。